Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CALCRLCHRM1CHRM2CHRM3F2RMAOAMAOBMAP2K1MAP2K2NTRK1NTRK2NTRK3OPRD1OPRK1OPRM1P2RY12PKLRSCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASLC18A2SLC6A2SLC6A3TLR7TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8dacAdacBdacCfolAftsImrcAmrcBmrdApolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmB1rpmB2rpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmHrpmIrpmJrpmJ2rpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsR1rpsR2rpsSrpsTrpsUrpsZykgMykgO
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.39 |
| ▸ | ALPI | P09923 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | XIAP | P98170 | 1/20 | 0.39 |
| ▸ | GRIA2 | P42262 | 5/20 | 0.37 |
| ▸ | GRIA1 | P42261 | 4/20 | 0.37 |
| ▸ | GRIA3 | P42263 | 4/20 | 0.37 |
| ▸ | GRIA4 | P48058 | 4/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BLM | P54132 | 2/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL503857 | 1.00 | SLC7A5 (0.43) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL9797596 | 0.98 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL9797579 | 0.98 | SLC7A5 (0.42) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL31519559 | 0.94 | SLC7A5 (0.39) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL17874427 | 0.94 | SLC7A5 (0.41) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL17874426 | 0.94 | SLC7A5 (0.41) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL18824897 | 0.94 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL995910 | 0.94 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3259 | 0.94 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL163442 | 0.94 | SLC7A5 (0.47) | SLC7A5CYP3A4CYP1A2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 845 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2026-03-17 | — | — | US | claimed |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | HANGZHOU DAC BIOTECH CO., LTD (CN) | 2022-08-11 | — | — | US | claimed |
| EP-3986476-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2022-04-27 | — | — | EP | claimed |
| CN-114040781-A | Formulation of conjugate of TUBULYSIN derivative and cell binding molecule | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2021096278-A1 | LIQUID PHASE COMPOSITION FOR ANTIBODY DRUG | 삼성바이오에피스 주식회사 | 2021-05-20 | — | — | WO | claimed |
| CN-108865913-A | A method of building efficient secretory expression chondroitin sulfate hydrolase recombinant bacterium | 江南大学 | 2018-11-23 | — | — | CN | claimed |
| US-20180000932-A1 | FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES | NOVELMED THERAPEUTICS INC (US) | 2018-01-04 | — | — | US | claimed |
| EP-3240571-A1 | FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES | NovelMed Therapeutics, Inc. (US) | 2017-11-08 | — | — | EP | claimed |
| WO-2016109822-A1 | FORMULATION OF AGLYCOSYLATED THERAPEUTIC ANTIBODIES | NOVELMED THERAPEUTICS, INC. (US) | 2016-07-07 | — | — | WO | claimed |
| US-7799900-B2 | humanized and chimeric anti-CD20 antibodies for treatment of CD20 positive malignancies and autoimmune diseases; treatment of B-cell associated diseases | GENENTECH, INC. (US) | 2010-09-21 | — | — | US | claimed |
| JP-4351674-B2 | — | — | 2009-10-28 | — | — | JP | claimed |
| US-20090214561-A1 | Treatment method | HOFFMANN-LA ROCHE INC. | 2009-08-27 | — | — | US | claimed |
| US-20090155257-A1 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | GENENTECH, INC. (US) | 2009-06-18 | — | — | US | claimed |
| WO-2009040268-A1 | FIXED SINGLE INJECTION DOSAGE FOR OCRELIZUMAB (2H7) | F. HOFFMANN-LA ROCHE AG (CH) | 2009-04-02 | — | — | WO | claimed |
| JP-2006517399-A | — | — | 2006-07-27 | — | — | JP | claimed |
| EP-1572744-A4 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | GENENTECH INC (US) | 2006-07-12 | — | — | EP | claimed |
| US-20060034835-A1 | Immunoglobulin variants and uses thereof | GENENTECH, INC. (US) | 2006-02-16 | — | — | US | claimed |
| EP-1572744-A2 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | GENENTECH, INC. (US) | 2005-09-14 | — | — | EP | claimed |
| WO-2004056312-A2 | IMMUNOGLOBULIN VARIANTS AND USES THEREOF | GENENTECH, INC. (US) | 2004-07-08 | — | — | WO | claimed |
| EP-0407045-A1 | Safe sodium percarbonate composition | TOKAI DENKA KOGYO KABUSHIKI KAISHA (JP) | 1991-01-09 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12576124-B2 | Formulation of a conjugate of a tubulysin analog to a cell-binding molecule | CD4, TAP1, MCTS1 | SLC7A5 157/4885CYP3A4 4877/4885CYP1A2 4885/4885 |
| US-20220249594-A1 | A FORMULATION OF A CONJUGATE OF A TUBULYSIN ANALOG TO A CELL-BINDING MOLECULE | CD4, TEKT1, NTSR1 | SLC7A5 1110/4885CYP3A4 4774/4885CYP1A2 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.